The translatome of neuronal cell bodies, dendrites, and axons DOI Creative Commons
Caspar Glock, Anne Biever, Georgi Tushev

и другие.

Proceedings of the National Academy of Sciences, Год журнала: 2021, Номер 118(43)

Опубликована: Окт. 20, 2021

Significance Proteins are the key drivers of neuronal synaptic function. The regulation gene expression is important for formation and modification synapses throughout lifespan. complexity dendrites axons imposes unique challenges protein supply at remote locations. discovery messenger RNAs (mRNAs) ribosomes near has shown that local synthesis represents an solution to this challenge. Here we used RNA sequencing ribosome determine directly population mRNAs present in process translation cell bodies, dendrites, axons. Thousands transcripts were differentially translated between body regions with over 800 exhibiting more dendritic–axonal compartment.

Язык: Английский

A brave new world of RNA-binding proteins DOI
Matthias W. Hentze, Alfredo Castelló, Thomas Schwarzl

и другие.

Nature Reviews Molecular Cell Biology, Год журнала: 2018, Номер 19(5), С. 327 - 341

Опубликована: Янв. 17, 2018

Язык: Английский

Процитировано

1500

mRNA vaccines for infectious diseases: principles, delivery and clinical translation DOI Open Access
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead

и другие.

Nature Reviews Drug Discovery, Год журнала: 2021, Номер 20(11), С. 817 - 838

Опубликована: Авг. 25, 2021

Язык: Английский

Процитировано

1022

The Discovery of Ribosome Heterogeneity and Its Implications for Gene Regulation and Organismal Life DOI Creative Commons
Naomi R. Genuth, Maria Barna

Molecular Cell, Год журнала: 2018, Номер 71(3), С. 364 - 374

Опубликована: Авг. 1, 2018

Язык: Английский

Процитировано

441

The promise of mRNA vaccines: a biotech and industrial perspective DOI Creative Commons

Nicholas A. C. Jackson,

Kent E. Kester,

Danilo R. Casimiro

и другие.

npj Vaccines, Год журнала: 2020, Номер 5(1)

Опубликована: Фев. 4, 2020

Abstract mRNA technologies have the potential to transform areas of medicine, including prophylaxis infectious diseases. The advantages for vaccines range from acceleration immunogen discovery rapid response and multiple disease target manufacturing. A greater understanding quality attributes that dictate translation efficiency, as well a comprehensive appreciation importance delivery, are influencing new era investment in development activities. application translational sciences growing early-phase clinical experience continue inform candidate vaccine selection. Here we review state art prevention diseases by using pertinent topics biotechnology pharmaceutical industries.

Язык: Английский

Процитировано

433

Advances in COVID-19 mRNA vaccine development DOI Creative Commons
Enyue Fang, Xiaohui Liu, Miao Li

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2022, Номер 7(1)

Опубликована: Март 23, 2022

Abstract To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 deaths worldwide. COVID-19 is a serious threat to human health globally. The World Health Organization (WHO) declared pandemic major public emergency. Vaccination most effective economical intervention for controlling spread of epidemics, consequently saving lives protecting population. Various techniques have been employed in development vaccines. Among these, messenger RNA (mRNA) vaccine drawing increasing attention owing its great application prospects advantages, which include short cycle, easy industrialization, simple production process, flexibility respond new variants, capacity induce better immune response. This review summarizes current knowledge on structural characteristics, antigen design strategies, delivery systems, industrialization potential, quality control, latest clinical trials real-world data mRNA vaccines as well technology. Current challenges future directions preventive infectious diseases are also discussed.

Язык: Английский

Процитировано

422

m6A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2 DOI Creative Commons
Yuanhui Mao, L. Dong, Xiaomin Liu

и другие.

Nature Communications, Год журнала: 2019, Номер 10(1)

Опубликована: Ноя. 25, 2019

Abstract Dynamic mRNA modification in the form of N 6 -methyladenosine (m A) adds considerable richness and sophistication to gene regulation. The m A mark is asymmetrically distributed along mature mRNAs, with approximately 35% residues located within coding region (CDS). It has been suggested that methylation CDS slows down translation elongation. However, neither decoding feature endogenous mRNAs nor physiological significance clearly defined. Here, we found leads ribosome pausing a codon-specific manner. Unexpectedly, removing from these transcripts results further decrease translation. systemic analysis RNA structural datasets revealed positively regulates by resolving secondary structures. We demonstrate elongation-promoting effect requires helicase-containing reader YTHDC2. Our findings established uncovered non-overlapping function proteins.

Язык: Английский

Процитировано

331

Human 5′ UTR design and variant effect prediction from a massively parallel translation assay DOI
Paul Sample, Ban Wang, David W. Reid

и другие.

Nature Biotechnology, Год журнала: 2019, Номер 37(7), С. 803 - 809

Опубликована: Июль 1, 2019

Язык: Английский

Процитировано

328

mRNA vaccines for COVID-19: what, why and how DOI Creative Commons
Jung Woo Park,

Philip N.P. Lagniton,

Yu Liu

и другие.

International Journal of Biological Sciences, Год журнала: 2021, Номер 17(6), С. 1446 - 1460

Опубликована: Янв. 1, 2021

The Coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2), has impacted human lives in the most profound ways with millions of infections and deaths.Scientists pharmaceutical companies have been race to produce vaccines against SARS-CoV-2.Vaccine generation usually demands years developing testing for efficacy safety.However, it only took less than one year generate two mRNA from their development deployment.The rapid production time, cost-effectiveness, versatility vaccine design, clinically proven ability induce cellular humoral immune response crowned spotlights as promising candidates fight pandemic.In this review, we discuss general principles design working mechanisms vaccines, provide an up-to-date summary pre-clinical clinical trials on seven anti-COVID-19 candidate focus already licensed vaccination.In addition, highlight key strategies designing maximize expression immunogens avoid intrinsic innate response.We also some perspective future COVID-19 other pathogens.

Язык: Английский

Процитировано

279

Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor DOI Creative Commons
Olusegun O. Onabajo, Abdul Rouf Banday, Megan L. Stanifer

и другие.

Nature Genetics, Год журнала: 2020, Номер 52(12), С. 1283 - 1293

Опубликована: Окт. 19, 2020

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, utilizes angiotensin-converting enzyme (ACE2) for entry into target cells. ACE2 has been proposed as an interferon-stimulated gene (ISG). Thus, interferon-induced variability in expression levels could be important susceptibility to COVID-19 or its outcomes. Here, we report the discovery of a novel, transcriptionally independent truncated isoform ACE2, designate deltaACE2 (dACE2). We demonstrate that dACE2, but not is ISG. In The Cancer Genome Atlas, dACE2 was enriched squamous tumors respiratory, gastrointestinal and urogenital tracts. vitro, lacks 356 amino-terminal amino acids, non-functional binding SARS-CoV-2 spike protein carboxypeptidase. Our results suggest ISG-type induction IFN-high conditions created by treatments, inflammatory tumor microenvironment viral co-infections unlikely increase cellular promote infection. newly identified unable bind protein. Truncated full-length induced interferons viruses, thus suggesting such are SARS-CoV-2.

Язык: Английский

Процитировано

253

Novel approaches for vaccine development DOI Creative Commons
Makda S. Gebre,

Luis A. Brito,

Lisa H. Tostanoski

и другие.

Cell, Год журнала: 2021, Номер 184(6), С. 1589 - 1603

Опубликована: Март 1, 2021

Язык: Английский

Процитировано

250